HIGHLIGHTS
- who: Neeltje van Doremalen from the multitude of different pathogens by the University of OxfordA vaccine based on this vector named ChAdOx, nCo, (also known as AZD1222, Vaxzevria, or Covishield) has been developed against severe acute respiratory syndrome coronavirus , (SARSCoV-2), the etiological agent of COVID-19. The efficacy of ChAdOx, nCo, has been shown in several randomized controlled clinical trials12-14. Furthermore, more than, ., billion doses of ChAdOx, nCo, vaccinations have been distributed to more than , countries, and it is the most widely used vaccine in the Covax program, which focuses on global equitable access to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.